Acquisition by Nicholas Maestas of 200000 shares of Tempest Therapeutics at 0.86 subject to Rule 16b-3
| TPST Stock | USD 0.95 0.09 10.47% |
Slightly above 54% of Tempest Therapeutics' private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Tempest Therapeutics suggests that some traders are interested. Tempest Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Tempest Therapeutics' earnings reports, geopolitical events, and overall market trends.
Tempest |
Filed transaction by Tempest Therapeutics Officer: Chief Financial Officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Tempest Therapeutics Fundamental Analysis
We analyze Tempest Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tempest Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tempest Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash And Equivalents
Cash And Equivalents Comparative Analysis
Tempest Therapeutics is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Tempest Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tempest Therapeutics stock to make a market-neutral strategy. Peer analysis of Tempest Therapeutics could also be used in its relative valuation, which is a method of valuing Tempest Therapeutics by comparing valuation metrics with similar companies.
Peers
Tempest Therapeutics Related Equities
| INDP | Indaptus Therapeutics | 6.32 | ||||
| RZLT | Rezolute | 4.22 | ||||
| AKTX | Akari Therapeutics | 2.17 | ||||
| ANEB | Anebulo Pharmaceuticals | 1.23 | ||||
| RVMD | Revolution Medicines | 1.12 | ||||
| PCSA | Processa Pharmaceuticals | 1.06 | ||||
| RNXT | RenovoRx | 0.72 | ||||
| ARMP | Armata Pharmaceuticals | 0.96 | ||||
| CGEM | Cullinan Oncology | 1.87 | ||||
| LYEL | Lyell Immunopharma | 2.94 | ||||
| IKNA | Ikena Oncology | 3.01 | ||||
| ZNTL | Zentalis Pharmaceuticals | 4.47 | ||||
| OLMA | Olema Pharmaceuticals | 4.73 | ||||
| GLUE | Monte Rosa | 5.22 | ||||
| SANA | Sana Biotechnology | 5.71 | ||||
| FBRX | Forte Biosciences | 8.10 |
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.